Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pfizer

The FDA authorized a second booster dose of COVID-19 vaccines made by Pfizer (PFE)/BioNTech (BNTX) and Moderna (MRNA) for older adults and some immunocompromised individuals.

FDA Authorizes Pfizer, Moderna's Second COVID Booster Dose

Moderna hopes its combination vaccine for COVID and the flu can keep profits high but investors are skeptical. MRNA stock struck gold with its Covid-19 vaccine but investors want to know if there are any other blockbusters in its pipeline.

Investors Seek Second Act with Moderna Stock

BioNTech SE

The FDA expands its authorization for both companies' coronavirus vaccines.

Why Moderna and BioNTech Were Winners Today

Moderna Inc (NASDAQ: MRNA) shares are trading higher by 4.67% at $181.16 after the company received FDA approval for Emergency Use Authorization for a second booster dose of its COVID-19 vaccine. Moderna announced Tuesday morning it has received approval from the U.S. Food and Drug Administration (.

Here's Why Moderna Shares Are Rising

The FDA has approved a second round of the Moderna Inc (NASDAQ: MRNA) or Pfizer Inc (NYSE: PFE), and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccines for older people and certain immunocompromised individuals.  The agency said the new boosters would be.

FDA Authorizes Fourth Dose Of Moderna, Pfizer/BioNTech COVID-19 Vaccines For Older People

Both Moderna and Pfizer received authorization for a second booster.

FDA Authorizes Second COVID Booster for Older Adults, Some Immunocompromised People

The FDA said the shots may be given to adults over 50 at least four months after they have received their first booster dose.

FDA authorizes 2nd booster shots of Pfizer and Moderna COVID-19 vaccines for older adults and immunocompromised people

The U.S. Food and Drug Administration said Tuesday it has authorized a second booster dose of either the Pfizer/BioNTech PFE, +0.69% BNTX, +3.77% or Moderna MRNA, +3.53% COVID-19 vaccines for people aged 50 and older. The agency has also authorized a second booster for people aged 12 and older who are immunocompromised and at risk of developing severe illness.

FDA authorizes second COVID vaccine booster shot for people 50 and older

Pfizer and Moderna's applications for a second Covid booster shot for older people was supported by real-world studies in Israel, which found that a second booster dramatically increased resistance to the delta and omicron strains.

FDA Authorizes 2nd Covid Booster For Americans 50 And Older

The Food and Drug Administration (FDA) on Tuesday authorized another COVID-19 booster shot for people ages 50 and older.

Second booster dose of Pfizer, Moderna COVID-19 vaccines authorized by FDA

50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age CAMBRIDGE, MA / ACCESSWIRE / March 29, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for its amendment to the emergency use authorization (EUA) to allow for a second booster dose of its COVID-19 vaccine (mRNA-1273) at the 50 µg dose level in adults 50 years of age and older who have received an initial booster of any of the authorized or approved COVID-19 vaccines and adults 18 years of age and older with certain kinds of immunocompromise. "The FDA's endorsement of a second booster dose will allow millions of Americans to build and maintain protection against SARS-CoV-2," said Stéphane Bancel, Chief Executive Officer of Moderna.

Moderna Receives FDA Approval for Emergency Use Authorization of 2nd Booster Dose of Its COVID-19 Vaccine, mRNA-1273

They offer us clues about near-term and long-term revenue.

Should You Buy Moderna? Look at These 2 Charts First.

The not-so-great side effects of Moderna's flu vaccine candidate could have greater implications.

Moderna Could Have a Big Problem on Its Hands

Moderna Inc. (NASDAQ:MRNA) and Pfizer Inc. (NYSE:PFE) has been highly popular stocks since the outbreak of COVID-19. Their development of vaccines against the virus results in significant gains for the investors.

Is Moderna a better buy compared to Pfizer?

While MRNA stock has been trending higher in recent weeks, questions remain about Moderna's pipeline and senior management team. The post Moderna's Stock Needs a Shot in the Arm appeared first on InvestorPlace.

Moderna's Stock Needs a Shot in the Arm

Are These 2 Rivals Beating Pfizer and Moderna?

Moderna, Inc. (MRNA) CEO Stephane Bancel Presents on Third Annual Vaccines Day Conference (Transcript)

WASHINGTON--(BUSINESS WIRE)--AHF: Moderna Dodges Shareholders with Virtual AGM

AHF: Moderna Dodges Shareholders with Virtual AGM

One analyst blasted Moderna's flu vaccine results as a "non-starter" clinically, while others said investors are still too focused on Covid.

Moderna Stock Plunges Despite 'Vaccine Day' Touting 31 New Shots And $21 Billion In Sales—Here's Why

Novavax

Investors appear to be concerned that Uncle Sam won't foot the bill for additional COVID-19 vaccine purchases.

Why Moderna, BioNTech, and Novavax Stocks Are Tumbling Today

AmerisourceBergen

CVS Health

These three fundamentally sound companies will protect both your vitals and your financial livelihood for years to come.

3 Healthcare Stocks With Healthy Fundamentals

A fresh business update didn't excite investors.

Why Moderna Stock Trailed the Market Today

Moderna will be seeking regulatory approval for its young children's COVID-19 vaccines, ahead of Pfizer.

Recovery Is Possible As Moderna Races Its Children Vaccine

Moderna's (MRNA) COVID-19 vaccine, mRNA-1273, generates robust neutralizing antibody response in a phase II/III study evaluating it in children.

Moderna (MRNA) to File EUA for Use of mRNA-1273 in Children

"You have people that are younger adults that have comorbidity factors, and they might need [a] sooner fourth dose to protect them," CEO Stephane Bancel told CNBC.

News for Moderna Stock (MRNA)